[Saralasin in resistant hypertensive crisis (author's transl)].
4 patients with hypertensive crisis (glomerulonephritis [n = 2], phaeochromocytoma [n = 1], reno-vascular hypertension [n = 1] combined with encephalopathy, showed a normalisation of blood-pressure up to 18 days during angiotensin-II-blockade with saralasin. Prior, blood pressure was treated insufficiently by intravenous diazoxide and Na-nitroprusside. Increased plasma-renin-activity and plasma levels of catecholamines pointed to an activation of the renin-angiotensin- and sympathico-adrenergic system. A trial of therapy with saralasin--especially, if blood-pressure response to diazoxide and sodium-nitroprusside is insufficient--could be indicated. Side-effects like pressor-reactions are excluded by very low priming doses (0,1 microgram/kg/min); rebound-hypertension at the end of the therapy is avoided by an overlapping therapy with renin suppressing drugs (beta-receptor blockers, clonidine, guanfacinum).
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000804:Angiotensin II / Q000031:analogs & derivatives*; D003000:Clonidine / Q000627:therapeutic use; D005260:Female; D005665:Furosemide / Q000627:therapeutic use; D005921:Glomerulonephritis / Q000150:complications; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D006978:Hypertension, Renovascular / Q000188:drug therapy; D008297:Male; D010673:Pheochromocytoma / Q000150:complications; D012504:Saralasin / Q000627:therapeutic use*; D000092502:Renin Inhibitors
D000319:Adrenergic beta-Antagonists; D000804:Angiotensin II; D003000:Clonidine; D005665:Furosemide; D012504:Saralasin; D000092502:Renin Inhibitors
Saralasin bei resistenten hypertensiven Krisen.